The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Patient-reported outcome collections continue to yield more effective and personalized treatments for patients with cancer.

Conversations surrounding fertility preservation may differ between young men and women with cancer, according to Donna Herrera Bell, MSN, APRN, FNP-C.

The CD40 agonist sotigalimab in combination with pembrolizumab yielded promising outcomes in patients with unresectable stage III or IV metastatic melanoma.

Pacritinib helps relieve physical function-related symptoms in adult patients with myelofibrosis and moderate or severe thrombocytopenia.

Patients with heavily pretreated lymphoma experienced promising clinical responses following treatment with the innate cell engager AMF13 plus preactivated and expanded natural killers (NK) cells.

Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, highlights the importance of relatlimab/nivolumab’s recent FDA approval in melanoma.

Oncology Nursing News® speaks with Hussein A. Tawbi, MD, PhD, principal investigator of the phase 2/3 RELATIVITY-046 trial, about the significance of the relatlimab/nivolumab approval for patients with unresectable or metastatic melanoma.

LAG-3 represents a potentially relevant immune checkpoint pathway in melanoma treatment.

Encouraging response rates were observed among patients with BRAF V600E–mutant metastatic colorectal cancer who received a triplet regimen of nivolumab, encorafenib, and cetuximab.

Dr. Hussein Tawbi, MD, PhD, explains the rationale behind the RELATIVITY-047 trial in melanoma and how the LAG-3 findings could further revolutionize immunotherapy.

An expert from The University of Texas MD Anderson Cancer Center offers advice on the best diet to enrich a patient’s microbiome and consequent immunotherapy response.

Ibrutinib plus rituximab is effective, easy to administer, and removes the need for chemotherapy in older patients, say experts.

An expert from The University of Texas MD Anderson Cancer Center highlights findings demonstrating the impact that diet and probiotics have in immunotherapy responses.

New data support increased fiber consumption and decreased probiotic use among patients receiving immunotherapy.

A novel regimen of relatlimab, an LAG-3 inhibitor, plus nivolumab doubled progression-free survival in patients with untreated, advanced melanoma.

David Hui, MD, MSc, from The University of Texas MD Anderson Cancer Center, discusses findings indicating that patients with agitated delirium may be under-sedated, in accordance with their personalized sedation goal.

An expert discusses the value of enrolling patients with soft tissue sarcoma in histologically specific clinical trials.

David Hui, MD, MSc, from The University of Texas MD Anderson Cancer Center, discusses how caregivers may prioritize communication when making end-of-life sedation decisions for loved ones with agitated delirium.

Trilaciclib was associated with reduced chemotherapy-induced myelosuppression and the need for associated supportive care in patients with a subtype of lung cancer.

David Hui, MD, MSc, from The University of Texas MD Anderson Cancer Center, discusses the impacts of personal sedation goals for caregivers of patients with cancer experiencing end-of-life agitated delirium.

Newer modalities seek to use MRD to provide more definitive prognoses.

A recent study found that nurses demonstrated a higher preference for deep sedation to treat patients with cancer-related delirium, compared with caregivers.

An expert from The University of Texas MD Anderson Cancer Center recently highlighted the ramifications of the phase 2 ReDOS trial, the need for molecular profiling in mCRC, and ongoing research on the combination of TKIs and checkpoint inhibitors.

Updates from the ongoing S1619 trial suggest that a triplet combination regimen of neoadjuvant cisplatin, pemetrexed, and atezolizumab is effective and tolerable in the treatment of patients with resectable pleural mesothelioma.

Patients with metastatic melanoma treated with the IL-2 agonist experienced a 78.5% change in target lesion size.

Cabozantinib exposure was not a predictor of progression-free survival was related to high rate of palmar-plantar plantar erythrodysesthesia and diarrhea in patients with advanced renal cell carcinoma.

Age was associated with overall survival and the time to Richter transformation in adolescent and young adult patients with chronic lymphocytic leukemia, according to findings from a single-institutional, retrospective study.

Novel therapeutics have not only boosted outcomes in myelofibrosis, but paved the way for new combination treatment strategies, too.

The HER2-positive breast cancer treatment paradigm is constantly changing, explained Debu Tripathy, MD, who cited that in less than 1 year, there have been 2 exciting drug approvals, which are tucatinib (Tukysa) and fam-trastuzumab deruxtecan-nxki (Enhertu).

Researchers are working on a way to spark the immune response against glioblastoma, making the nurses’ role in treatment even more important.